Open access · OA
via Europe PMC
The Bidirectional Role of Cellular Senescence in the Treatment of Ovarian Cancer.
Yuan D, Chen M, Wei J, Zhang Y, Li Y, Tang N, Han C, Zhou Y.
Biomedicines · 2026
Genomic instability
Telomere attrition
Epigenetic alterations
Cellular senescence
Stem-cell exhaustion
Altered intercellular communication
Partial reprogramming (OSK)
Human
Review
Abstract
Cellular senescence(definition) plays a complex and crucial dual role in ovarian cancer treatment: it serves as both an important tumor suppression mechanism and a potential driver of drug resistance and recurrence. This review systematically examines the intricate regulatory network of cellular senescence, encompassing multiple pathways including telomere(definition) dysfunction, DNA damage response, epigenetic remodeling, hormone signaling, and metabolic reprogramming. Studies have demonstrated that core therapeutic modalities, such as platinum-based chemotherapy, PARP inhibitors, and CDK4/6 inhibitors, can exert anti-tumor effects by inducing cellular senescence; however, their efficacy is significantly influenced by the senescence-associated secretory phenotype (SASP). Specific SASP components can activate immune surveillance, whereas others promote tumor progression, acquisition of stem cell-like characteristics, and therapeutic resistance. It is this "anti-tumor versus pro-tumor" paradox that renders senescent cells a critical variable determining treatment outcomes. In light of this, emerging strategies aim to precisely modulate the senescence process, including the use of epigenetic drugs to induce senescence, targeting metabolic vulnerabilities to eliminate senescent cells, and intervening in deleterious SASP to improve the tumor microenvironment. Integrating such strategies with conventional therapies holds promise for overcoming the resistance bottleneck in ovarian cancer and opening new avenues for improving patient prognosis.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3390/biomedicines14081797
- Canonical
- link ↗
- Fetched
- 2026-10-08 MST
Cite this
APA
D, Y., M, C., J, W., Y, Z., Y, L., N, T., C, H., & Y., Z. (2026). The Bidirectional Role of Cellular Senescence in the Treatment of Ovarian Cancer. <em>Biomedicines</em>. https://doi.org/10.3390/biomedicines14081797
Vancouver
D Y, M C, J W, Y Z, Y L, N T, et al. The Bidirectional Role of Cellular Senescence in the Treatment of Ovarian Cancer. Biomedicines. 2026. doi:10.3390/biomedicines14081797.
BibTeX
@article{yuan2026TheBid,
title = {The Bidirectional Role of Cellular Senescence in the Treatment of Ovarian Cancer.},
author = {Yuan D and Chen M and Wei J and Zhang Y and Li Y and Tang N and Han C and Zhou Y.},
journal = {Biomedicines},
year = {2026},
doi = {10.3390/biomedicines14081797},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Redox Biology 2021
Open access · CC-BY
The redox-senescence axis and its therapeutic targeting
Cells 2024
Open access · CC-BY
Therapy-Induced Cellular Senescence: Potentiating Tumor Elimination or Driving Cancer Resistance and Recurrence?
Diabetes 2015
Preprint · OA
Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity
Cancer Cell 2025
Open access · CC-BY
Senescence in cancer
Aging and disease 2026
Citation only
Senescence and SASP in the Stromal Microenvironment of Breast Cancer: Dual Role in Progression and Therapeutic Options.
Cancer Science 2019
Open access · CC-BY